Navigation Links
Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
Date:8/14/2008

- Phase 2 development to begin in late 2008 or in early 2009 -

SAN CARLOS, Calif., Aug. 14 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced positive results from the Phase 1b proof-of-concept trial of NU172, demonstrating that the direct thrombin inhibitor rapidly produced and maintained anticoagulation with a rapid return toward baseline after the infusion ended with a favorable safety profile.

"NU172 has the potential to address many of the limitations of currently available anticoagulants given the profile we have seen to date in preclinical and Phase 1 testing, including its ability to produce rapid and predictable onset and offset of anticoagulation without the need for an antidote, its potential ability to work in stagnant blood, its predominately non-renal clearance, and the option to stop and restart anticoagulation as needed during or after surgery," said A. Michael Lincoff, M.D., vice chairman of the department of cardiovascular medicine and an interventional cardiologist at the Cleveland Clinic. "Because of these characteristics, NU172 could potentially offer an improved approach to anticoagulation for procedures such as coronary artery bypass graft (CABG) surgery, kidney dialysis, and percutaneous coronary intervention (PCI)."

The single-center, Phase 1b trial examined the safety, tolerability and pharmacokinetics of intravenous bolus plus infusion dosing of NU172, in 24 healthy male volunteers. Volunteers were given a 2 mg/kg bolus dose followed by escalating infusion doses of NU172 for four hours. In all four cohorts, NU172 produced dose-dependent increases in anticoagulation, measured by activated clotting time (ACT), prothrombin time (PT) and activated partial thromboplastin tim
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
2. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. NewCardio Announces Positive Results From Third Clinical Validation Study
10. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... OAKS, Calif. , June 19, 2013 Amgen ... the United States , Canada ... this year,s recipients of the Amgen Award for Science Teaching ... extraordinary teachers at the kindergarten through 12th grade level who ... in science education. With a long-standing commitment to ...
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... oral Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients ... lymphoma (SLL). Ibrutinib was shown to be safe and ... in patients who were at high-risk due to factors ...
(Date:6/19/2013)...   NextDocs announced today that it will ... at DIA 2013 , the Drug Information Association ... studies that explore best practices for making the transition ... file (eTMF) systems. Sharon Ames , ... Krystyna Kowalczyk , executive vice president of clinical operations ...
Breaking Medicine Technology:Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 2Amgen Award For Science Teaching Excellence Honors Outstanding Teachers 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6NextDocs and Novella to Present on eTMF at DIA 2013 2
(Date:6/19/2013)... STRATFORD, Conn (PRWEB) June 20, 2013 A man ... same man he used to be. In his debut book titled ... a war veteran who immerses himself back home, looking for the ... When Gabriel De Los Angeles, former marine from the Vietnam War, ... to take the edge off his PTSD. Wings, a wealthy acquaintance ...
(Date:6/19/2013)... Across the globe billions of people live ... the medical advances that benefit developed western society. ... and the necessary aid to help curb the conditions ... Outlook with Ben Kingsley is partnering with some ... these people live and highlight the invaluable resources being ...
(Date:6/19/2013)... 2013 HASCO Medical, Inc. (OTCBB: ... intent to purchase privately held Auto Mobility Sales, ... wheelchair accessible vehicle sales, service and rentals in ... Inc compliments and expands HASCO's strategy of becoming ... dealers . The acquisition is subject to customary ...
(Date:6/19/2013)... 2013 Kleritec, Inc. announced the addition ... http://www.kleritec.com . In the recent expansion Kleritec ... activities packages for pre-school and day care providers. The ... to aid teachers across the United States the ability ... , Included in the art and activities packages is ...
(Date:6/19/2013)... Citi Bike has come to New York City in ... to know for sure how many patients will choose to take ... the option. In fact, he’s happy about anything that might ... it more convenient for them to visit his office at 133 ... Alternative Medicine at Back and Body Medical and an experienced ...
Breaking Medicine News(10 mins):Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2Health News:HASCO Medical, Inc. to Acquire Auto Mobility Sales, Inc. 2Health News:Kleritec Announces Addition of Educational Products. 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3
... Cuts Will Reduce Access to Care for Millions ... , , ARLINGTON, Va., Sept. 16 ... recommendations for healthcare reform in his long-awaited "Chairman,s mark" version of ... home medical equipment, ranging from power wheelchairs to anti-fraud measures. The ...
... strong disapproval of contraception might be a factor , ... are higher in states with greater levels of religious ... new U.S. study suggests. , In the study, researchers ... on teen birth rates with data from the Pew ...
... , PANAMA CITY, Fla., Sept. 16 ... staff washing their hands when moving from patient to patient can ... Commission , handwashing failures contribute to healthcare-associated infections ... hospitals $4 billion to $29 billion annually to combat. At ...
... , MINNEAPOLIS, Sept. 16 Today ClearWay ... and thanked outgoing members for their service to the organization. David ... as the new Board Chair. The full roster of Board Officers ... David Fisher, Board Chair - An attorney ...
... , , , SAN DIEGO, ... Diego based medical device company, today announced that its application for ... technology has been approved by the Food and Drug Administration. The ... , , Jim Hitchin, SpectraScience,s, CEO said, ...
... InVitria to ... in Animal Cells (PEACe) in Jackson Hole, WY, Sept. 19-23. , ... Fort Collins, CO (PRWEB) September 16, 2009 -- InVitria ... supplements at the 9th Annual PEACe conference to be held in Jackson Hole, WY, Sept. ...
Cached Medicine News:Health News:Senate Finance Committee Cuts Home Medical Equipment in Reform Package 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 2Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 3Health News:Bay Medical Fights Healthcare-Associated Infections by Improving Hand Hygiene 300% 4Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:SpectraScience Receives FDA Approval for Enhancements to WavSTAT(R) Optical Biopsy System 2Health News:InVitria Cell Culture Product Line to Headline PEACe 2
... 1 Block MBS Start up kit. ... software and choice of 1 MultiBlock ... to 30 blocks. User friendly software. ... Adjustable height heated lid. Outstanding ...
0.2ml Gradient Block MBSR. Robot compatible block ejection mechanism. Stackable. (96 well block - holds 1 plate 0.2ml x 96 well plate)...
96 well format, Gradient features tests 12 PCR annealing temperatures in 1 run...
... The latest addition to our ... cyclers is the personal-sized GeneAmp ... instrument for both basic PCR ... represents the culmination of several ...
Medicine Products: